Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jun 1;25(11):3469-3470.
doi: 10.1158/1078-0432.CCR-19-0402.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 + Regulatory T Cells (Tregs) in Human Cancers-Response

Affiliations
Free PMC article
Comment

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 + Regulatory T Cells (Tregs) in Human Cancers-Response

Anu Sharma et al. Clin Cancer Res. .
Free PMC article

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

S.K. Subudhi reports receiving speakers bureau honoraria from Valeant Pharmaceuticals International and the University of Texas Health Science Center at Taylor; holds ownership interest (including patents) in Apricity Health LLC; and is a consultant/advisory board member for Bayer Health-Care Pharmaceuticals, Dendreon, and Driver Inc. J.A. Wargo reports receiving speakers bureau honoraria from Dava Oncology, Illumina, Roche Genentech, Bristol-Myers Squibb, Merck, Gilead, MedImmune, and PHE; and is a consultant/advisory board member for Novartis, Bristol-Myers Squibb, AstraZeneca, Roche Genentech, and Merck. J.P. Allison holds ownership interest (including patents) in Jounce, Neon, Forty-Seven, ImaginAb, Tvardi Therapeutics, Constellation Pharmaceuticals, BioAtla, Polaris Pharmaceuticals, Hummingbird Bioscience, Merck, Amgen, Aparicity Therapeutics; has immediate family members who hold ownership interest in Jounce, Neon, Constellation, Oncolytics Biotech, Merck, BioMX, BioAtla, Forty-Seven, Aparicity, Polaris, Marker, ImaginAb, Hummingbird, Pieris Pharmaceuticals, Amgen, and Codiak; is a consultant/advisory board member for Jounce, Neon, BioAtla, Codiak, Tvardi, Amgen, Forty-Seven, ImaginAb, Merck, and Hummingbird; and has immediate family members who are consultant/advisory board members for Jounce, Constellation, Neon, BioAtla, Pieris, Oncolytics, Merck, BioMX, Forty-Seven, Aparicity, Polaris, Marker Therapeutics, Codiak, Hummingbird, AstraZeneca, Amgen, and GlaxoSmithKline. A. Ribas is a consultant/advisory board member for Merck, Bristol-Myers Squibb, Amgen, Chugai, Arcus, FLX-Bio, Five Prime, and Compugen. P. Sharma holds ownership interest in Jounce, Neon, Constellation, Oncolytics Biotech, BioAtla, Forty-Seven, Aparicity, Polaris, Marker, ImaginAb, Hummingbird, Optera, Dragonfly and Codiak and is a consultant/advisory board member for Jounce, Constellation, Neon, BioAtla, Pieris, Merck, Forty-Seven, Aparicity, Polaris, Marker Therapeutics, Codiak, Hummingbird, ImaginAb, Optera and Dragonfly; she also reports an immediate family member holding ownership interest in Jounce, Neon, BioAtla, Forty-Seven, Aparicity, Polaris, Marker Therapeutics, Codiak, ImaginAb, Hummingbird, Tvardi Therapeutics, Optera, and Dragonfly and consultant/advisory board membership in Jounce, BioAtla, Neon, Amgen, Forty-Seven, Aparicity, Polaris, Marker Therapeutics, Codiak, ImaginAb, Tvardi Therapeutics, Hummingbird, Merck, BMS, Optera, and Dragonfly. No potential conflicts of interest were disclosed by the other authors.

Figures

Figure 1.
Figure 1.
Effect of ipilimumab on CTLA-4–expressing FOXP3+CD4+ T cells in human melanoma. The proportion of CTLA-4–expressing FOXP3+CD4+ T cells was compared using multiparametric CyTOF analysis in pre- and post-ipilimumab-treated melanoma samples (N = 5). The dot plots represent mean with SD, and each dot represents an individual patient sample.
Figure 2.
Figure 2.
Effect of ipilimumab on density of intratumoral FOXP3+ cells in responders versus nonresponders. Ipilimumab-treated melanoma samples from nonresponders (NR; N = 7) and responders (R; N = 4) were analyzed by IHC for the density of intratumoral FOXP3+ cells. The dot plots represent mean with SD, and each dot represents an individual patient sample.

Comment on

Similar articles

See all similar articles

Cited by 5 articles

LinkOut - more resources

Feedback